Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Percutaneous renal biopsy (PRB) in metastatic renal cell carcinoma (MRCC) patients with acute kidney injury (AKI) on systemic anticancer therapy
    Meeting Abstract

    Milanez, T.; Arnol, M.; Premru, V.; Kojc, N.; Ocvirk, J.; Ovcaricek, T.; Jaimes, E.
    Nephrology Dialysis Transplantation (2023)

    Fulltext@MSK | Save
  • KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
    Meeting Abstract

    Wakelee, H. A.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; He, J.; Gao, S.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Westin, J.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S. N.; Martin, A. G.; Jung, K. H.; Lugowska, I. A.; Manso, L.; Manzano, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Tomczak, P.; Suáez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Procopio, G.; Mahammedi, H.; Zengerling, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
    Meeting Abstract

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Okamoto, I.; Inoue, T.; Cid, J. R. R.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)
    Meeting Abstract

    Schrag, D.; Shi, Q.; Weiser, M. R.; Gollub, M. J.; Saltz, L. B.; Musher, B. L.; Goldberg, J.; Al Baghdadi, T.; Goodman, K. A.; McWilliams, R. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • An AI predictive model to determine who benefits from ADT with radiation: Working smarter, not harder
    Editorial

    Slovin, Susan F.
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and its impact on patient overall survival: Findings from 10,551 patients in the ARCAD database
    Journal Article

    Ou, F. S.; Ahn, D. H.; Dixon, J. G.; Grothey, A.; Lou, Y.; Kasi, P. M.; Hubbard, J. M.; Van Cutsem, E.; Saltz, L. B.; Schmoll, H. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save